Hagop M. Kantarjian, MD of MD Anderson Cancer Center’s Department of Leukemia gives the trial overview and conclusions of Pfizer’s newly approved FDA CD22-directed antibody-drug conjugate Besponsa (Inotuzumab Ozogamicin) for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Besponsa (Inotuzumab Ozogamicin) Trial Overview & Conclusions – Hagop M. Kantarjian, MD
